Richard Watson
Managing Partner @ Furthr VC
Richard Watson is a seed investor at Furthr VC focused on Medical Device and Medical. Richard is Managing Partner at Furthr VC, one of the most active early-stage VC investors in the country. He has worked in venture capital for over 15 years and, prior to this, spent almost a decade in industry in R&D and operations in the medical device and semiconductor industries in Sweden, Ireland and the US.Richard has a 1st classhonours degree in Electronic Engineering from Trinity College Dublin, a Research M.Sc. in Biomedical Engineering from Trinity College Dublin and a 1st class MBA from Durham University.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Richard Watson invests in
Stages Richard Watson invests in
Countries Richard Watson invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical Device 5 (36%)
- Medical 4 (29%)
- Health Care 3 (21%)
- SaaS 1 (7%)
- Retail 1 (7%)
Stage
- Seed 7 (50%)
- Funding Round 2 (14%)
- Series A 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
WrxFlo
|
Wrxflo provides software solutions that connect operations and management systems, visualizing data through customizable dashboards. The company specializes in business and productivity software, offering an IoT platform tailored for the manufacturing industry. Wrxflo's solutions enable businesses to access and manage their data efficiently,enhancing operational insights and decision-making processes. | $3.4M / Venture - Series Unknown / Jul 07, 2026 | |
Neurobell
|
NeuroBell are developing a novel medical device providing portable EEG monitoring with real-time &automated neonatal seizure alerts at the bedside. | $5.5M / Jun 29, 2026 | |
|
Neurobell
|
NeuroBell are developing a novel medical device providing portable EEG monitoring with real-time &automated neonatal seizure alerts at the bedside. | $2.1M / Seed / Jan 08, 2024 | |
Bluedrop Medical
|
It has been estimated that up to 25% of diabetics will develop a foot ulcer at some point in their life. One of the main causes is peripheral neuropathy, which results in a patient losing sensation in their feet. Of the millions who develop ulcers every year, hundreds of thousands will require amputation due to infection. In 2014, Ireland recordedan increase in the number of amputations as a result of diabetes, with 8 limbs being lost every week. | $11.4M / Seed / Mar 31, 2023 | |
MEG
|
MEG delivers audit management, incident reporting, risk management, and policy and document management services for the healthcare sector. | $797.2K / Seed / Dec 28, 2022 | |
Everyangle
|
Everyangle facilitates business in computer vision applications based on cisco meraki MV smart cameras across retail and industrial firms. | $2.7M / Seed / Oct 30, 2022 | |
Evercam
|
SaaS platform for managing cameras on construction sites. Project Management, Dispute Avoidance & Marketing | $8.8M / Venture - Series Unknown / Oct 23, 2022 | |
Ronspot
|
Ronspot is a desk and parking booking system company. | $1.1M / Seed / Sep 02, 2022 | |
Gasgon Medical
|
Gasgon Medical is a medical device company that launches new products to support medical staff and deliver improved patient outcomes. Gasgon tackles the challenges of improving IV infusions for patients and clinicians, with the goal of achieving a future in which all IV medicine can be infused with confidence. Gasgon improves healthcare performanceby learning from and supporting medical staff, allowing them to provide better patient outcomes. | $2.4M / Seed / Apr 26, 2022 | |
SymPhysis Medical
|
SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer. | $2M / Seed / Apr 25, 2022 | |
| See all 14 investments → | |||
Co-Investors
About Furthr VC
We are a relationship driven early stage VC investor. We invest in and form close partnerships with the founders we back.We make initial investments at Seed to Series A stage in highly ambitious, born global Irish software and medtech companies. We are hands-on and support teams across key strategic areas to accelerate growth.In addition toproviding institutional investment at an early stage, we reserve significant capital for following on in subsequent rounds. We go the journey with founders.
Furthr VC Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Richard Watson
Managing Partner
|
|||
Colm O'Sullivan
Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Richard Watson invest in?
Richard Watson invests primarily in Medical Device, Medical and Health Care startups, most often at Seed and Funding Round stage. Most of the 14 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Richard Watson?
Public channels for Richard Watson include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Richard Watson last invest?
The most recent investment recorded for Richard Watson closed in Jul 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
